Methyl 7-bromoindolizine-2-carboxylate

Catalog No.: 
ACTDMP251
CAS No.: 
1620570-14-0
Molecular Formula: 
C10H8BrNO2
Molecular Weight: 
254.08
Methyl 7-bromoindolizine-2-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25mg95%$116.00In stockInquiry
50mg95%$197.00In stockInquiry
100mg95%$335.00In stockInquiry
250mg95%$568.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameMethyl 7-bromoindolizine-2-carboxylate
IUPAC Namemethyl 7-bromoindolizine-2-carboxylate
Molecular FormulaC10H8BrNO2
Molecular Weight254.08
SMILESO=C(C1=CN2C=CC(Br)=CC2=C1)OC
InChI KeyLYNDANZNIPKZAW-UHFFFAOYSA-N
Synonym2-Indolizinecarboxylic acid, 7-bromo-, methyl ester;Methyl 7-bromoindolizine-2-carboxylate
CAS No.1620570-14-0

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACTDMP251 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACQVKH312 route compound structure diagram
    ACQVKH3121184-54-9In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTDMP251 route product structure diagram
    ACTDMP2511620570-14-0In Stock
Inquiry

2. ACTDMP251 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTDMP251 route product structure diagram
    ACTDMP2511620570-14-0In Stock
Inquiry

3. ACTDMP251 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTDMP251 route product structure diagram
    ACTDMP2511620570-14-0In Stock
Inquiry

Comments (0)